Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 754 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Side Effects Clear all
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 8, 2026, 4:45 PM EDT
Completed No phase listed Observational Results available

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT01015326
View directory record Official record
Conditions
Skin Toxicities
Interventions
Questionnaire
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 8, 2026, 4:45 PM EDT
Withdrawn Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase

NCT03791580
View directory record Official record
Conditions
Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
Interventions
Commitment nudge, Justification nudge
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

NCT00007670
View directory record Official record
Conditions
Seizures
Interventions
Carbamazepine, Gabapentin, Lamotrigine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 8, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional Results available

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

NCT00090844
View directory record Official record
Conditions
Breast Cancer, Hormone Changes, Drug Toxicity
Interventions
triptorelin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
Up to 44 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Oakland, California • Tampa, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Method of Fish Oil Administration on Patient Compliance

NCT01471366
View directory record Official record
Conditions
Adverse Effects
Interventions
Frozen capsule, Capsule with food, Capsule without food, Capsule with milk
Dietary Supplement
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Smell Changes & Efficacy of Nasal Theophylline

NCT03990766
View directory record Official record
Conditions
Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use, Smell Disorder
Interventions
Theophylline, Saline Nasal
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 8, 2026, 4:45 PM EDT
Enrolling by invitation Not applicable Interventional

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

NCT06069154
View directory record Official record
Conditions
Rib Fracture, Rib Fracture Multiple
Interventions
Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block
Device · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 4:45 PM EDT
Completed No phase listed Observational

Perceptions of Side Effects of Cancer Chemoradiotherapy

NCT02978846
View directory record Official record
Conditions
Malignant Neoplasm, Side Effect
Interventions
Clinical Observation
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 8, 2026, 4:45 PM EDT
Not listed Phase 2 Interventional

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

NCT00061152
View directory record Official record
Conditions
HIV Infections
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
West Hollywood, California • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2007 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine

NCT06441695
View directory record Official record
Conditions
Caffeine, Cognitive Change, Mood, Mood Change
Interventions
xumXR extended release caffeine, immediate release caffeine
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
35 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 8, 2026, 4:45 PM EDT
Not yet recruiting Phase 2 Interventional

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

NCT07572175
View directory record Official record
Conditions
Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 8, 2026, 4:45 PM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 8, 2026, 4:45 PM EDT
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 8, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

NCT06902311
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
Interventions
Breast Radiotherapy
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

NCT00317798
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
anti-thymocyte globulin, sirolimus
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Personal Health Records and Elder Medication Use Quality

NCT02012712
View directory record Official record
Conditions
Adverse Reaction to Drug, Health Behavior, Medication Adherence, Physician-Patient Relations
Interventions
Personal Health Record (PHR)
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
65 Years to 95 Years
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

NCT04209075
View directory record Official record
Conditions
Diabetes
Interventions
Biomebliss, Metformin, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Side Effects of Atropine (SEA) Study

NCT03593044
View directory record Official record
Conditions
Myopia
Interventions
0.01% concentration atropine drops
Drug
Lead sponsor
Jeffrey J. Walline, OD PhD
Other
Eligibility
21 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 8, 2026, 4:45 PM EDT
Terminated Phase 4 Interventional

Pain Control After Minimally Invasive Coronary Artery Bypass Grafting

NCT01770236
View directory record Official record
Conditions
Postoperative Pain, Medication Side Effects, Narcotic Requirement
Interventions
IV acetaminophen
Drug
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 8, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 8, 2026, 4:45 PM EDT
Active, not recruiting Phase 2 Interventional

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Infliximab, Placebo, Relatlimab, Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 4:45 PM EDT